BIOSIMILARS Two biosimilars get US panel's nod

被引：0
|
作者：
Mccoy, Michael
机构：
来源：
CHEMICAL & ENGINEERING NEWS | 2016年 / 94卷 / 29期
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [1] Get the most from biosimilars
    Traynor, Kate
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2024, 81 (18) : 794 - 794
  • [2] US to accept biosimilars?
    Houlton, Sarah
    CHEMISTRY & INDUSTRY, 2007, (13) : 6 - 6
  • [3] US debut for biosimilars
    Houlton, Sarah
    CHEMISTRY & INDUSTRY, 2015, 79 (04) : 25 - 25
  • [4] PRICES OF BIOSIMILARS IN THE US
    Gannu, L.
    Daniels, K.
    Seoane-Vazquez, E.
    Szeinbach, S. L.
    VALUE IN HEALTH, 2017, 20 (05) : A33 - A33
  • [5] Challenges with the Introduction of Biosimilars in the US
    Stevenson, James G.
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2016, 8 (03) : 93 - 96
  • [6] Biosimilars: The US Regulatory Framework
    Christl, Leah A.
    Woodcock, Janet
    Kozlowski, Steven
    ANNUAL REVIEW OF MEDICINE, VOL 68, 2017, 68 : 243 - 254
  • [7] WILL US PAYERS CHAMPION BIOSIMILARS?
    Malik, A. N.
    Cox, J.
    Keeping, K.
    VALUE IN HEALTH, 2015, 18 (03) : A265 - A265
  • [8] Biosimilars Regulation in the US: The Challenges
    Ridley-Smith, Philip
    BIOPHARM INTERNATIONAL, 2010, 23 (11) : 58 - 58
  • [9] Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations
    Pivot, Xavier
    Aulagner, Gilles
    Blay, Jean Yves
    Fumoleau, Pierre
    Kaliski, Alexandre
    Sarkozy, Francois
    Limat, Samuel
    ANTI-CANCER DRUGS, 2015, 26 (10) : 1009 - 1016
  • [10] No two classes of biosimilars: Urgent advice to the US Congress and the FDA
    Niazi, Sarfaraz K.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (09) : 1352 - 1361
12345